

Expanding Access to Treatment for Hepatitis C in Resource-Limited Settings: A Review of the Literature HIV/AIDS

Clinical Infectious Diseases

54, 1465-1472

DOI: [10.1093/cid/cis227](https://doi.org/10.1093/cid/cis227)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Challenges and Priorities in the Management of HIV/HBV and HIV/HCV Coinfection in Resource-Limited Settings. <i>Seminars in Liver Disease</i> , 2012, 32, 147-157.	3.6	34
2	Why Should Infectious Disease Physicians Care for the Hepatitis C-Infected Patient?. <i>Infectious Disease Clinics of North America</i> , 2012, 26, 839-847.	5.1	1
3	Increasing Hepatitis C treatment uptake among HIV-infected patients using an HIV primary care model. <i>AIDS Research and Therapy</i> , 2013, 10, 9.	1.7	19
4	Update on HIV/HCV Coinfection. <i>Current HIV/AIDS Reports</i> , 2013, 10, 226-234.	3.1	48
5	Limited Access to Protease Inhibitors Therapy for Chronic HCV in the Region: YES. <i>Current Hepatitis Reports</i> , 2013, 12, 280-287.	0.3	3
6	The changing face of hepatitis C in the new era of direct-acting antivirals. <i>Antiviral Research</i> , 2013, 97, 36-40.	4.1	24
8	Hepatitis B and C Co-Infection among HIV-Infected Adults while on Antiretroviral Treatment: Long-Term Survival, CD4 Cell Count Recovery and Antiretroviral Toxicity in Cambodia. <i>PLoS ONE</i> , 2014, 9, e88552.	2.5	48
9	Healthcare workers's experiences of HIV testing in Tshwane, South Africa. <i>Curationis</i> , 2014, 37, 1170.	0.7	7
10	Hepatitis C, A Global Issue: Access to Care and New Therapeutic and Preventive Approaches in Resource-Constrained Areas. <i>Seminars in Liver Disease</i> , 2014, 34, 089-097.	3.6	34
11	Simplification of antiviral hepatitis C virus therapy to support expanded access in resource-limited settings. <i>Journal of Hepatology</i> , 2014, 61, S132-S138.	3.7	30
12	Forgotten, not neglected: viral hepatitis in resource-limited settings, recall for action. <i>Liver International</i> , 2014, 34, 12-15.	3.9	19
13	Lack of Access to Treatment as a Barrier to HCV Screening. <i>Journal of Public Health Management and Practice</i> , 2014, 20, 420-423.	1.4	6
14	Functional foods effective for hepatitis C: Identification of oligomeric proanthocyanidin and its action mechanism. <i>World Journal of Hepatology</i> , 2014, 6, 870.	2.0	14
15	Pegylated Interferon Pharmacokinetics and Self-Reported Depressive Symptoms During Antiviral Treatment for Chronic Hepatitis C. <i>Pharmacopsychiatry</i> , 2014, 47, 195-201.	3.3	9
16	Do the epidemiology, physiological mechanisms and characteristics of hepatocellular carcinoma in HIV-infected patients justify specific screening policies?. <i>Aids</i> , 2014, 28, 1379-1391.	2.2	25
17	Minimum Costs for Producing Hepatitis C Direct-Acting Antivirals for Use in Large-Scale Treatment Access Programs in Developing Countries. <i>Clinical Infectious Diseases</i> , 2014, 58, 928-936.	5.8	197
18	HCV transmission in industrialized countries and resource-constrained areas. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2014, 11, 28-35.	17.8	93
19	Antiviral treatment of hepatitis C. <i>BMJ</i> , The, 2014, 349, g3308-g3308.	6.0	175

#	ARTICLE	IF	CITATIONS
20	Effectiveness and Cost-effectiveness of Immediate Versus Delayed Treatment of Hepatitis C Virus-Infected Patients in a Country With Limited Resources: The Case of Egypt. <i>Clinical Infectious Diseases</i> , 2014, 58, 1064-1071.	5.8	34
21	Hepatitis C can be cured globally, but at what cost?. <i>Science</i> , 2014, 345, 141-142.	12.6	60
22	A phase 1, randomized, dose-ranging study of GS-5816, a once-daily NS5A inhibitor, in patients with genotype 4 hepatitis C virus. <i>Journal of Viral Hepatitis</i> , 2015, 22, 1011-1019.	2.0	51
23	Building Bridges for Collective Wisdom. <i>Journal of Global Oncology</i> , 2015, 1, 1-2.	0.5	3
24	Hepatitis C genotype 4: The past, present, and future. <i>World Journal of Hepatology</i> , 2015, 7, 2792.	2.0	41
25	Rational Design and Adaptive Management of Combination Therapies for Hepatitis C Virus Infection. <i>PLoS Computational Biology</i> , 2015, 11, e1004040.	3.2	19
26	Diagnostics for resource-limited settings in the era of interferon-free HCV therapy. <i>Journal of Viral Hepatitis</i> , 2015, 22, 459-460.	2.0	4
27	Milestones along the road of infection prevention in Egypt. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2015, 34, 1923-1928.	2.9	0
28	Novel Humanitarian Aid Program: The Glivec International Patient Assistance Program—Lessons Learned From Providing Access to Breakthrough Targeted Oncology Treatment in Low- and Middle-Income Countries. <i>Journal of Global Oncology</i> , 2015, 1, 37-45.	0.5	38
29	Hepatitis C seroprevalence and HIV co-infection in sub-Saharan Africa: a systematic review and meta-analysis. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 819-824.	9.1	107
30	A Public Health Approach to Hepatitis C Control in Low- and Middle-Income Countries. <i>PLoS Medicine</i> , 2015, 12, e1001795.	8.4	32
31	Clinical impact of treatment timing for chronic hepatitis C infection: a decision model. <i>Journal of Viral Hepatitis</i> , 2015, 22, 630-638.	2.0	8
32	An Epidemiologic Investigation of a Case of Acute Hepatitis E. <i>Journal of Clinical Microbiology</i> , 2015, 53, 3547-3552.	3.9	11
33	Global distribution and prevalence of hepatitis C virus genotypes. <i>Hepatology</i> , 2015, 61, 77-87.	7.3	1,293
34	Hepatitis C Virus Treatment Access Among Human Immunodeficiency Virus and Hepatitis C Virus (HCV)-Coinfected People Who Inject Drugs in Guangzhou, China: Implications for HCV Treatment Expansion. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw065.	0.9	8
35	Hepatitis C in HIV-infected individuals: a systematic review and meta-analysis of estimated prevalence in Africa. <i>Journal of the International AIDS Society</i> , 2016, 19, 20711.	3.0	19
36	High Proportion of HIV-HCV Coinfected Patients with Advanced Liver Fibrosis Requiring Hepatitis C Treatment in Haiphong, Northern Vietnam (ANRS 12262). <i>PLoS ONE</i> , 2016, 11, e0153744.	2.5	12
37	Estimating the Impact of Expanding Treatment Coverage and Allocation Strategies for Chronic Hepatitis C in a Direct Antiviral Agent Era. <i>PLoS ONE</i> , 2016, 11, e0163095.	2.5	10

#	ARTICLE	IF	CITATIONS
38	Systematic review and meta-analysis of hepatitis C virus infection in the Democratic Republic of Congo. <i>Public Health</i> , 2016, 139, 13-21.	2.9	15
39	Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes. <i>World Journal of Gastroenterology</i> , 2016, 22, 7824.	3.3	621
40	Public health and international drug policy. <i>Lancet, The</i> , 2016, 387, 1427-1480.	13.7	460
41	Cost-Effectiveness Modelling of Sofosbuvir-Containing Regimens for Chronic Genotype 5 Hepatitis C Virus Infection in South Africa. <i>Pharmacoeconomics</i> , 2016, 34, 403-417.	3.3	13
42	The prevalence of hepatitis C virus infection in Egypt 2015: implications for future policy on prevention and treatment. <i>Liver International</i> , 2017, 37, 45-53.	3.9	193
43	HCV management in resource-constrained countries. <i>Hepatology International</i> , 2017, 11, 245-254.	4.2	10
44	Rationing hepatitis C treatment in the context of austerity policies in France and Cameroon: A transnational perspective on the pharmaceuticalization of healthcare systems. <i>Social Science and Medicine</i> , 2017, 187, 243-250.	3.8	11
45	Discovery and preclinical development of dasabuvir for the treatment of hepatitis C infection. <i>Expert Opinion on Drug Discovery</i> , 2017, 12, 635-642.	5.0	13
46	Study of inhibition of interferon inducible genes by dephosphorylation of E2 envelope gene of HCV genotype 1a. , 2017, , .		0
47	Prevalence of hepatitis B and C infection in persons living with HIV enrolled in care in Rwanda. <i>BMC Infectious Diseases</i> , 2017, 17, 315.	2.9	34
48	Hepatitis C Virus (HCV) genotypes distribution among hepatocellular carcinoma patients in Southern Italy: a three year retrospective study. <i>Infectious Agents and Cancer</i> , 2017, 12, .	2.6	14
49	RAPID AND EARLY VIROLOGICAL RESPONSE OF PATIENTS TREATED WITH SOFOSBUVIR IN CHRONIC HEPATITIS C.. <i>Pakistan Journal of Medical Sciences</i> , 2017, 33, 813-817.	0.6	3
50	Is hepatitis C virus elimination possible among people living with <scp>HIV</scp> and what will it take to achieve it?. <i>Journal of the International AIDS Society</i> , 2018, 21, e25062.	3.0	39
51	Mobilising a global response to hepatitis: Lessons learned from the HIV movement. <i>Global Public Health</i> , 2018, 13, 473-488.	2.0	3
52	Prevalence of hepatitis C among HIV-1, HIV-2 and dually reactive patients: A multi-country cross-sectional survey in West Africa. <i>Journal of Public Health in Africa</i> , 2018, 9, 871.	0.4	2
53	Previous incarceration impacts access to hepatitis C virus (HCV) treatment among HIV&HCV co&infect&infected patients in Canada. <i>Journal of the International AIDS Society</i> , 2018, 21, e25197.	3.0	18
54	Overcoming barriers to hepatitis C elimination. <i>Frontline Gastroenterology</i> , 2019, 10, 207-209.	1.8	20
55	Hepatitis C â€œ New drugs and treatment prospects. <i>European Journal of Medicinal Chemistry</i> , 2019, 165, 225-249.	5.5	66

#	ARTICLE	IF	CITATIONS
56	In-field evaluation of Xpert® HCV viral load Fingerstick assay in people who inject drugs in Tanzania. <i>Liver International</i> , 2020, 40, 514-521.	3.9	22
57	Safety and Efficacy of Limited Laboratory Monitoring for Hepatitis C Treatment: A Blinded Clinical Trial in Rwanda. <i>Hepatology Communications</i> , 2020, 4, 569-576.	4.3	0
58	High prevalence and genotype distribution of hepatitis C virus in people living with HIV in Kathmandu, Nepal. <i>Infectious Diseases</i> , 2021, 53, 1-10.	2.8	3
59	Elimination of Viral Hepatitis in Low and Middle-Income Countries: Epidemiological Research Gaps. <i>Current Epidemiology Reports</i> , 2021, 8, 89-96.	2.4	9
60	Harvoni: A Combination Therapy for Curing HCV. , 2017, , 558-582.		3
61	“Waiting for DAAs” A retrospective chart review of patients with untreated hepatitis C in Rwanda. <i>PLoS ONE</i> , 2017, 12, e0174148.	2.5	9
62	Capacity of non-invasive hepatic fibrosis algorithms to replace transient elastography to exclude cirrhosis in people with hepatitis C virus infection: A multi-centre observational study. <i>PLoS ONE</i> , 2018, 13, e0192763.	2.5	20
63	Use of Ribavirin for Hepatitis C Treatment in the Modern Direct-acting Antiviral Era. <i>Journal of Clinical and Translational Hepatology</i> , 2018, 6, 1-7.	1.4	18
64	Barriers to access to hepatitis C treatment. <i>Journal of Infection in Developing Countries</i> , 2016, 10, 308-316.	1.2	11
65	Hepatitis C: a changing epidemic. <i>Swiss Medical Weekly</i> , 2015, 145, w14093.	1.6	32
66	Pathway to affordable, quality-assured sources of pegylated interferon alpha for treating hepatitis C. <i>GaBI Journal</i> , 2013, 2, 194-203.	0.3	2
67	Generic Direct Acting Antiviral Treatment: The First Step Towards Elimination of Hepatitis C in Iran. <i>Hepatitis Monthly</i> , 2017, 17, .	0.2	12
68	Safety and Efficacy of Pegylated Interferon alpha-2a and Ribavirin Combination in Treatment of Egyptian Patients with Chronic Hepatitis C Genotype-4. <i>IOSR Journal of Pharmacy</i> , 2014, 04, 07-13.	0.1	0
69	The Challenges of Conquering Viral Hepatitis Beginning in Childhood: Introduction of the Rationale and Importance of Controlling Viral Hepatitis Starting from Children. , 2019, , 1-10.		0
70	Hepatitis C seroprevalence among people living with HIV/AIDS and pregnant women in four provinces in Cambodia: an integrated bio-behavioral survey. <i>BMC Infectious Diseases</i> , 2022, 22, 177.	2.9	2
71	Machine learning for prediction of viral hepatitis: A systematic review and meta-analysis. <i>International Journal of Medical Informatics</i> , 2023, 179, 105243.	3.3	0